Return to study ST002735 main page
MB Sample ID: SA288623
| Local Sample ID: | RS_13 |
| Subject ID: | SU002841 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Gender: | Male |
Select appropriate tab below to view additional metadata details:
Subject:
| Subject ID: | SU002841 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Gender: | Male |
Factors:
| Local Sample ID | MB Sample ID | Factor Level ID | Level Value | Factor Name |
|---|---|---|---|---|
| RS_13 | SA288623 | FL035600 | Pre-treatment | Factor |
Collection:
| Collection ID: | CO002834 |
| Collection Summary: | The study was approved by the Institutional Review Board of the College of Medicine, King Saud University, Riyadh, Saudi Arabia (registration no. E-18-3075). Recruited patients were asked to sign a written informed consent form before enrolling. Twenty patients who were diagnosed with T2DM were referred to the King Khaled University Hospital's (KKUH), Obesity Research Center, where this study took place. Patients were treated with an appropriate dose of Liraglutide for a three months as described previously (8). Samples were taken pre-treatment and post-treatment. Note: the T2DM participants were on other medications including insulin and metformin beside the Liraglutide treatment. |
| Collection Protocol Filename: | Liraglutide_sample_collection.docx |
| Sample Type: | Blood (plasma) |
Treatment:
| Treatment ID: | TR002850 |
| Treatment Summary: | Patients with indications of add-on liraglutide were started on treatment by their physician in a scaled-up dose from 0.6 mg to 1.8 mg of a once-daily subcutaneous injection over a period of three weeks. The follow-up visit was scheduled 3 months after receiving the full dose (1.8 mg) of liraglutide. Urine samples were collected at two time points: one sample before and another sample after treatment with liraglutide. Blood samples were collected by venipuncture into plain tubes (Vacutainer, BD Biosciences, San Jose, CA, USA) from each patient after a 10 h fast. The plasma was separated by centrifugation (15 min, 3000× g), divided into several aliquots, and stored at −80 °C for further analysis. |
| Treatment Compound: | Liraglutide |
Sample Preparation:
| Sampleprep ID: | SP002847 |
| Sampleprep Summary: | Metabolites were extracted from plasma were collected from 20 type2 diabetic patients, pre-and post-treatment with liraglutide (n=40 samples) (10). Briefly, 100 μL plasma sample were mixed with 900 μL of extraction solvent 50% acetonitrile (ACN) in methanol (MeOH). Meanwhile, QC samples were prepared with aliquots from all samples to check for system stability. The mixtures were mixed on thermomixer at 600 rpm at room temperature for one hour (Eppendorf, CITY, Germany). Afterward, the samples were centrifuged at 16000 rpm at 4ºC for 10 min. The supernatant was transferred into new Eppendrof tube, and then evaporated completely in a SpeedVac (Christ, Germany). The dried samples were reconstituted with100 μl of 50% mobile phase A: B (A: 0.1% Formic acid in dH2O, B: 0.1% Formic acid in 50% ACN: MeOH). |
| Sampleprep Protocol Filename: | Liraglutide_Metabolites_Extraction.docx |
Combined analysis:
| Analysis ID | AN004434 | AN004435 |
|---|---|---|
| Analysis type | MS | MS |
| Chromatography type | Reversed phase | Reversed phase |
| Chromatography system | Waters Acquity UPLC | Waters Acquity UPLC |
| Column | Waters XSelect HSS C18 (100 × 2.1mm,2.5um) | Waters XSelect HSS C18 (100 × 2.1mm,2.5um) |
| MS Type | ESI | ESI |
| MS instrument type | QTOF | QTOF |
| MS instrument name | Waters Xevo-G2-S | Waters Xevo-G2-S |
| Ion Mode | POSITIVE | NEGATIVE |
| Units | Peak area | Peak area |
Chromatography:
| Chromatography ID: | CH003331 |
| Methods Filename: | LC_MS_Metabolomics_Liraglutide.docx |
| Instrument Name: | Waters Acquity UPLC |
| Column Name: | Waters XSelect HSS C18 (100 × 2.1mm,2.5um) |
| Column Temperature: | 55 |
| Flow Gradient: | 0-16 min 95- 5% A, 16-19 min 5% A, 19-20 min 5-95% A, 20-22 min 95- 95% A |
| Flow Rate: | 300 µL/min |
| Solvent A: | 0.1% formic acid in dH2O |
| Solvent B: | 0.1% formic acid in 50% MeOH and ACN |
| Chromatography Type: | Reversed phase |
MS:
| MS ID: | MS004181 |
| Analysis ID: | AN004434 |
| Instrument Name: | Waters Xevo-G2-S |
| Instrument Type: | QTOF |
| MS Type: | ESI |
| MS Comments: | The DIA data were collected with a Masslynx™ V4.1 workstation in continuum mode (Waters Inc., Milford, MA, USA). The raw MS data were processed following a standard pipeline using the Progenesis QI v.3.0 software. |
| Ion Mode: | POSITIVE |
| Analysis Protocol File: | LC_MS_Metabolomics_Liraglutide.docx |
| MS ID: | MS004182 |
| Analysis ID: | AN004435 |
| Instrument Name: | Waters Xevo-G2-S |
| Instrument Type: | QTOF |
| MS Type: | ESI |
| MS Comments: | The DIA data were collected with a Masslynx™ V4.1 workstation in continuum mode (Waters Inc., Milford, MA, USA). The raw MS data were processed following a standard pipeline using the Progenesis QI v.3.0 software. |
| Ion Mode: | NEGATIVE |
| Analysis Protocol File: | LC_MS_Metabolomics_Liraglutide.docx |
